Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study

Figures & data

Table 1 Patients clinical and treatment data

Number	Age/sex	Position	KPS	NCC	IT	Response	Outcome	PFS	OS
1	72/F	PR1	80	9	RT + MTX	CR	Alive	15.4+	15.4+
2	49/F	ER	80	8	MTX	CR	Alive	12.4+	12.4+
3	67/M	PR1	80	9	MTX	CR	Alive	10.1	11.1+
4	67/F	ER	80	7	MTX	CR	Alive	6.8+	6.8+
5	67/F	ER	80	6	RT + MTX	CR	Alive	6.2	7.5+
6	77/M	ER	80	10	MTX	PR2	Death	11.2	11.2
7	60/F	ER	80	7	MTX	PR2	Alive	10.2+	10.2+
8	76/M	PR1	70	8	MTX	PR2	Alive	9.8	10.3
9	45/F	PR1	90	2	MTX	PR2	Death	7.8	8.6
10	80/F	PR1	70	5	MTX	PR2	Alive	6.2	7.8
11	81/F	ER	90	5	RT	SD	Death	3.8	7.1
12	70/M	ER	60	4	MTX	SD	Alive	5.2	5.2
13	69/M	PR1	70	3	RT + MTX	SD	Death	1.8	4.2
14	75/M	ER	80	3	MTX	SD	Death	2.1	3.9
15	35/M	MT	70	3	RT + MTX	PD	Death	6.6	6.6
16	58/F	ER	70	4	RT + MTX	PD	Death	5.7	5.7
17	78/M	PR1	60	1	RT + MTX	PD	Death	2.4	3.5

Abbreviations: CR, complete remission; ER, ectopic recurrence; F, female; IT, initial treatment; KPS, Karnofsky performance status; M, male; MT, metastasis; MTX, methotrexate; NCC, number of chemotherapy cycles; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR1, primary recurrence; PR2, partial remission; RT, radiotherapy; SD, stable disease.

Figure 1 The representative magnetic resonance imaging images of complete response patient before and after the pemetrexed treatment.

Figure 2 Overall survival of 17 recurrent primary central nervous system lymphoma patients treated with pemetrexed.

Table 2 Adverse events associated with pemetrexed (N=17)

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Leukoencephalopathy	0	0	0	0	0
ALT/AST	0	1	1	0	0
Infection	0	0	0	0	3
Anemia	2	0	0	0	0
Leukopenia	0	1	0	1	0
Thrombocytopenia	3	1	1	1	0
Nausea	0	1	1	0	0
Vomiting	1	0	2	0	0
Fatigue	2	2	1	0	0
Constipation	2	1	1	0	0

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.